Giuseppe Curigliano

Giuseppe Curigliano, MD, PhD, is director of the Early Drug Development Division and co-chair of the Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer centre in Milan, Italy. He is a steering committee member in the Department of Oncology and Hematology-Oncology at the University of Milan and a member of the Italian National Health Council. He is a past member of the expert panel issuing the Associazione Italiana di Oncologia Medica (AIOM), European Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) guidelines in breast cancer and germline gene testing recommendations. He is principal investigator and a steering committee member for numerous clinical trials, particularly with innovative targeted compounds and individualised treatment strategies. His translational research focusses on the field of biomarkers and personalised therapies. Professor Curigliano has authored more than 670 papers in peer-reviewed journals and many book chapters and has served as an editorial board member for international journals in oncology. He is a panel member of several international breast cancer consensus conferences and is currently editor-in-chief of ESMO Open and the president-elect of ESMO.